Insider Trends: Exelixis Insider Gets Shares Award Sells Portion for Taxes Slowing, 90-Day Buy Trend
10:48 PM EST, 02/05/2021 (MT Newswires) -- Dr Gisela Schwab, Pres, Prod Dev & Med Aff & Cmo, awarded 81,038 shares in Exelixis (EXEL) and sold 14,982 shares concurrently to meet tax obligations on Feb 03, 2021. After accounting for tax obligations this transaction resulted in a net acquisition of 66,056 company shares. Subsequent to the Form 4 filing with the SEC, Dr Schwab has control over 558,335 shares of the company of which 543,455 shares are held directly and 14,880 are controlled indirectly. These holdings have an approximate market value of $12.8 million as of the prior-day closing price.
In the 90 days previous to the date of this filing, there have been 21 insider transactions reported to the SEC for Exelixis. These transactions came from the activities of 8 individual insiders that resulted in a net acquisition of 22,881 company shares. This compares with the preceding 90-day window of time where there were 28 transactions from 8 insiders which resulted in the net acquisition of 279,727 shares.
This is less than the average level of insider transactions in the 324-company Bio Therapeutic Drugs peer group over the last 90-day period. Activity in the peer group averaged 56.3 transactions per company, with company insiders acquiring on average 24,490 shares.
SEC Story Link http://www.sec.gov/Archives/edgar/data/939767/000093976721000010/xslF345X03/wf-form4_161257775017168.xml
This report does not constitute a recommendation to purchase or sell any security and the analysts are not registered investment advisors. Further analysis is recommended before undertaking any position in any security. Any risks are solely the responsibility of the buyer/seller. The authors, publishers and distributors of the MT Newswires Live Briefs service and any associates thereof accept no liability for the content or actions taken by anyone or institution utilizing this report.